These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28698210)

  • 61. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
    Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
    Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cas12a Base Editors Induce Efficient and Specific Editing with Low DNA Damage Response.
    Wang X; Ding C; Yu W; Wang Y; He S; Yang B; Xiong YC; Wei J; Li J; Liang J; Lu Z; Zhu W; Wu J; Zhou Z; Huang X; Liu Z; Yang L; Chen J
    Cell Rep; 2020 Jun; 31(9):107723. PubMed ID: 32492431
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
    Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
    Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
    [TBL] [Abstract][Full Text] [Related]  

  • 64. APOBEC3A damages the cellular genome during DNA replication.
    Green AM; Landry S; Budagyan K; Avgousti DC; Shalhout S; Bhagwat AS; Weitzman MD
    Cell Cycle; 2016; 15(7):998-1008. PubMed ID: 26918916
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
    Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis.
    Wu J; Li N; Zhu L; Zhen D; Li M; Chen H; Ye M; Wei Y; Shao G
    BMC Bioinformatics; 2022 Aug; 23(1):312. PubMed ID: 35918642
    [TBL] [Abstract][Full Text] [Related]  

  • 68. APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer.
    McCann JL; Cristini A; Law EK; Lee SY; Tellier M; Carpenter MA; Beghè C; Kim JJ; Sanchez A; Jarvis MC; Stefanovska B; Temiz NA; Bergstrom EN; Salamango DJ; Brown MR; Murphy S; Alexandrov LB; Miller KM; Gromak N; Harris RS
    Nat Genet; 2023 Oct; 55(10):1721-1734. PubMed ID: 37735199
    [TBL] [Abstract][Full Text] [Related]  

  • 69. APOBEC3A/B deletion polymorphism and cancer risk.
    Gansmo LB; Romundstad P; Hveem K; Vatten L; Nik-Zainal S; Lønning PE; Knappskog S
    Carcinogenesis; 2018 Feb; 39(2):118-124. PubMed ID: 29140415
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
    Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
    Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
    Brachova P; Alvarez NS; Van Voorhis BJ; Christenson LK
    Gynecol Oncol; 2017 Jun; 145(3):577-583. PubMed ID: 28215840
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.
    Fanourakis G; Tosios K; Papanikolaou N; Chatzistamou I; Xydous M; Tseleni-Balafouta S; Sklavounou A; Voutsinas GE; Vastardis H
    Exp Mol Pathol; 2016 Dec; 101(3):314-319. PubMed ID: 27818121
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
    Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway.
    Yazinski SA; Zou L
    Annu Rev Genet; 2016 Nov; 50():155-173. PubMed ID: 27617969
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
    Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
    [TBL] [Abstract][Full Text] [Related]  

  • 77. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
    Wang S; Jia M; He Z; Liu XS
    Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
    Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
    Sieuwerts AM; Schrijver WA; Dalm SU; de Weerd V; Moelans CB; Ter Hoeve N; van Diest PJ; Martens JW; van Deurzen CH
    PLoS One; 2017; 12(1):e0171343. PubMed ID: 28141868
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
    Tokunaga E; Yamashita N; Tanaka K; Inoue Y; Akiyoshi S; Saeki H; Oki E; Kitao H; Maehara Y
    PLoS One; 2016; 11(12):e0168090. PubMed ID: 27977754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.